Merus (MRUS) Lowered to “Sell” at BidaskClub

Share on StockTwits

BidaskClub downgraded shares of Merus (NASDAQ:MRUS) from a hold rating to a sell rating in a research note issued to investors on Friday morning.

Other equities analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Merus from a hold rating to a buy rating and set a $22.00 price target on the stock in a report on Thursday, September 27th. ValuEngine upgraded shares of Merus from a hold rating to a buy rating in a report on Monday, July 2nd. Finally, Wedbush restated an outperform rating and set a $34.00 price target (up from $26.00) on shares of Merus in a report on Friday, July 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $28.50.

NASDAQ:MRUS traded down $0.32 during trading hours on Friday, hitting $15.71. 14,425 shares of the stock traded hands, compared to its average volume of 45,308. Merus has a fifty-two week low of $14.05 and a fifty-two week high of $26.74. The company has a market cap of $446.61 million, a P/E ratio of -3.66 and a beta of -0.19.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Thursday, July 26th. The biotechnology company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.33. Merus had a negative net margin of 178.79% and a negative return on equity of 67.34%. The business had revenue of $11.84 million for the quarter, compared to analysts’ expectations of $3.47 million. Analysts expect that Merus will post -2.6 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. California Public Employees Retirement System purchased a new position in shares of Merus during the 2nd quarter valued at $228,000. DRW Securities LLC bought a new stake in Merus in the second quarter worth $286,000. Millennium Management LLC bought a new stake in Merus in the first quarter worth $267,000. Renaissance Technologies LLC boosted its holdings in Merus by 26.8% in the second quarter. Renaissance Technologies LLC now owns 48,200 shares of the biotechnology company’s stock worth $1,097,000 after purchasing an additional 10,200 shares in the last quarter. Finally, Stanley Laman Group Ltd. boosted its holdings in Merus by 23.7% in the second quarter. Stanley Laman Group Ltd. now owns 57,396 shares of the biotechnology company’s stock worth $1,306,000 after purchasing an additional 10,982 shares in the last quarter. Institutional investors and hedge funds own 54.43% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Read More: Find a Trading Strategy That Works

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Merus  Lowered to “Sell” at BidaskClub
Merus Lowered to “Sell” at BidaskClub
Ligand Pharmaceuticals  Downgraded to “Hold” at BidaskClub
Ligand Pharmaceuticals Downgraded to “Hold” at BidaskClub
Home Bancorp  Upgraded by BidaskClub to “Sell”
Home Bancorp Upgraded by BidaskClub to “Sell”
Express Scripts  Upgraded to Strong-Buy at BidaskClub
Express Scripts Upgraded to Strong-Buy at BidaskClub
SURETY Price Reaches $0.0083
SURETY Price Reaches $0.0083
Brokerages Anticipate American Campus Communities, Inc.  to Post $0.44 Earnings Per Share
Brokerages Anticipate American Campus Communities, Inc. to Post $0.44 Earnings Per Share


Leave a Reply

© 2006-2018 Ticker Report. Google+.